SG11201901020RA - Anti-siglec-7 antibodies for the treatment of cancer - Google Patents
Anti-siglec-7 antibodies for the treatment of cancerInfo
- Publication number
- SG11201901020RA SG11201901020RA SG11201901020RA SG11201901020RA SG11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA
- Authority
- SG
- Singapore
- Prior art keywords
- suite
- california
- international
- shoreway
- san
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371680P | 2016-08-05 | 2016-08-05 | |
| PCT/US2017/045641 WO2018027203A1 (en) | 2016-08-05 | 2017-08-04 | Anti-siglec-7 antibodies for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901020RA true SG11201901020RA (en) | 2019-03-28 |
Family
ID=61073084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901020RA SG11201901020RA (en) | 2016-08-05 | 2017-08-04 | Anti-siglec-7 antibodies for the treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11773162B2 (https=) |
| EP (1) | EP3494142A4 (https=) |
| JP (1) | JP7137563B2 (https=) |
| KR (1) | KR20190035863A (https=) |
| CN (1) | CN109790223A (https=) |
| AU (1) | AU2017307616A1 (https=) |
| BR (1) | BR112019002331A2 (https=) |
| CA (1) | CA3032437A1 (https=) |
| EA (1) | EA201990296A1 (https=) |
| IL (1) | IL264674B2 (https=) |
| MX (1) | MX2019001471A (https=) |
| SG (1) | SG11201901020RA (https=) |
| WO (1) | WO2018027203A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| BR112019002331A2 (pt) | 2016-08-05 | 2019-06-18 | Allakos Inc | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| US11447545B2 (en) | 2017-07-10 | 2022-09-20 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US11912766B2 (en) * | 2018-01-11 | 2024-02-27 | Allakos, Inc. | Anti-Siglec-7 antibodies having reduced effector function |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021247821A1 (en) * | 2020-06-03 | 2021-12-09 | The Wistar Institute Of Anatomy And Biology | Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| JP2025027841A (ja) * | 2023-08-17 | 2025-02-28 | 国立大学法人 東京大学 | ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体 |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20070244038A1 (en) | 2006-04-12 | 2007-10-18 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| EP2172483A4 (en) * | 2007-07-04 | 2010-08-04 | Forerunner Pharma Res Co Ltd | ANTI-MUC17 ANTIBODY |
| BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| ES2791183T3 (es) * | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| WO2014188423A1 (en) * | 2013-05-21 | 2014-11-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
| MX383594B (es) | 2014-08-07 | 2025-03-14 | Daiichi Sankyo Co Ltd | Anticuerpo anti-orai1. |
| WO2016038064A1 (en) | 2014-09-10 | 2016-03-17 | Innate Pharma | Cross reactive siglec antibodies |
| KR20180054639A (ko) * | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| AU2017207807A1 (en) | 2016-01-12 | 2018-07-12 | Palleon Pharmaceuticals Inc. | Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer |
| EP3426688A1 (en) * | 2016-03-08 | 2019-01-16 | Innate Pharma | Siglec neutralizing antibodies |
| BR112019002331A2 (pt) | 2016-08-05 | 2019-06-18 | Allakos Inc | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos |
-
2017
- 2017-08-04 BR BR112019002331A patent/BR112019002331A2/pt not_active Application Discontinuation
- 2017-08-04 IL IL264674A patent/IL264674B2/en unknown
- 2017-08-04 CN CN201780060307.2A patent/CN109790223A/zh active Pending
- 2017-08-04 SG SG11201901020RA patent/SG11201901020RA/en unknown
- 2017-08-04 WO PCT/US2017/045641 patent/WO2018027203A1/en not_active Ceased
- 2017-08-04 US US16/323,442 patent/US11773162B2/en active Active
- 2017-08-04 MX MX2019001471A patent/MX2019001471A/es unknown
- 2017-08-04 JP JP2019527783A patent/JP7137563B2/ja active Active
- 2017-08-04 CA CA3032437A patent/CA3032437A1/en active Pending
- 2017-08-04 AU AU2017307616A patent/AU2017307616A1/en not_active Abandoned
- 2017-08-04 EA EA201990296A patent/EA201990296A1/ru unknown
- 2017-08-04 EP EP17837808.9A patent/EP3494142A4/en not_active Withdrawn
- 2017-08-04 KR KR1020197006520A patent/KR20190035863A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3494142A4 (en) | 2020-04-01 |
| US11773162B2 (en) | 2023-10-03 |
| IL264674B1 (en) | 2023-05-01 |
| WO2018027203A1 (en) | 2018-02-08 |
| MX2019001471A (es) | 2019-10-30 |
| JP2019526622A (ja) | 2019-09-19 |
| KR20190035863A (ko) | 2019-04-03 |
| EA201990296A1 (ru) | 2019-08-30 |
| US20190194323A1 (en) | 2019-06-27 |
| IL264674B2 (en) | 2023-09-01 |
| CN109790223A (zh) | 2019-05-21 |
| JP7137563B2 (ja) | 2022-09-14 |
| BR112019002331A2 (pt) | 2019-06-18 |
| IL264674A (https=) | 2019-03-31 |
| CA3032437A1 (en) | 2018-02-08 |
| EP3494142A1 (en) | 2019-06-12 |
| AU2017307616A1 (en) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201807785VA (en) | Neuroactive steroids, compositions, and uses thereof | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201810801QA (en) | Brain delivery protein |